Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated antibody products by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated antibody products by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

At-a-glance

Genmab’s Growing Organization & Growing Presence

Princeton, USA
- Translational Research
- Development
- Commercial
- Corporate Functions
Tokyo, JP
- Clinical
- Commercial
- Corporate Functions

Utrecht, NL
- Research
- Translational Research
- Antibody Product Creation
- Corporate Functions

Copenhagen, DK
- HQ
- CMC Operations
- Clinical Operations
- Corporate Functions

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated antibody products by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Our Purpose
To improve the lives of patients with cancer by creating and developing innovative and differentiated antibody products

Our Vision
By 2025, our own product has transformed cancer treatment, and we have a pipeline of knock-your-socks-off antibodies

Our Values
- Integrity – we do the right thing
- We work as one team & respect each other
- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Our Strategy

How we Operate

Team
Flexible and adaptive infrastructure

Research & Data Sciences
Key to accelerating development & ensuring the right therapies get to the right patients

Development
Scaling up capabilities to expand from early- to late-stage

Commercialization
Next step in our evolution

Enabling Functions:
- Support growth and manage risk
- Strong financials with growing recurring investment

Our Strengths and Differentiators

- World-class antibody biology knowledge and deep insight into disease targets
- Discovery and development engine with proprietary technologies that allow us to build a world-class pipeline
- In-house expertise with solid track record of building successful strategic partnerships
- Robust pipeline of potential best-in-class and first-in-class therapies
- Experienced, diverse management team

Operational

Approved Medicines Including Genmab’s Innovation

DARZALEX® developed & marketed by Janssen Biotech Inc. Kesimpta® developed & marketed by Novartis. TEPEZZA® developed & marketed by Horizon Therapeutics. RYSREVANT™ developed & marketed by Janssen Biotech Inc.

Proprietary Technologies

DuoBody® platform, HexaBody® platform, DuoHexaBody® platform & HexElect® platform

Proprietary Antibody Products in Clinical Development

Tisotumab vedotin, epcortamab, DuoBody-PD-L1x4-1BB (GEN1048), DuoBody-CD40x4-1BB (GEN1042), HexaBody-DR5/DR5 (GEN1029), DuoHexaBody-CD37 (GEN3009), DuoBody-CD3x5T4 (GEN1044), HexaBody-CD38 (GEN3014)

Product Candidates Built on Genmab’s Innovation

In clinical development with other companies and royalty streams for Genmab should they come to market. Includes 7 DuoBody products with Janssen

Financial

DKK
161B
2020 year-end market cap

DKK
16,079M
2020 year-end cash position

DKK
10,111M
2020 revenue
88% increase versus 2019

DKK
3,798M
2020 operating expenses
83% invested in R&D

Operating Result

(DKK million)

2016
2017
2018
2019
2020
1,053
1,344
1,380
2,638
6,313
### Genmab Proprietary Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Developed by</th>
<th>Indications</th>
<th>Most Advanced Dev. Phase</th>
<th>Appr.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epontamab</td>
<td>CD3, CD20</td>
<td>Co-developed Genmab/AbbVie Inc.</td>
<td>R/R DLBCL, Hem. malig, B-cell NHL (combo R/R CLL)</td>
<td>I/II II III</td>
<td></td>
</tr>
<tr>
<td>DuoBody-PD-L1x4-1BB</td>
<td>PD-L1, 4-1BB</td>
<td>Co-developed Genmab/ BioNTech</td>
<td>Solid tumors</td>
<td>II III</td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD40x4-1BB</td>
<td>CD40, 4-1BB</td>
<td>Co-developed Genmab/ BioNTech</td>
<td>Solid tumors</td>
<td>II III</td>
<td></td>
</tr>
<tr>
<td>HexaBody-DR5/DR5</td>
<td>DR5</td>
<td>Genmab</td>
<td>Solid tumors</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD3xST4</td>
<td>ST4</td>
<td>Co-developed Genmab/AbbVie Inc.</td>
<td>Solid tumors</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>HexaBody-CD38</td>
<td>CD38</td>
<td>Genmab</td>
<td>Hem. malig.</td>
<td>II</td>
<td></td>
</tr>
</tbody>
</table>

### Approved Medicines Created by Genmab

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Developed by</th>
<th>Indication(s)</th>
<th>Most Advanced Dev. Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daratumumab</td>
<td>CD38</td>
<td>Janssen</td>
<td>MM³, AL Amyloidosis, Non-MM blood cancers</td>
<td>I/II II III III</td>
</tr>
<tr>
<td>Ofatumumab</td>
<td>CD20</td>
<td>Novartis</td>
<td>RMS³</td>
<td>I/II II III III</td>
</tr>
<tr>
<td>Teprotumumab</td>
<td>IGF-1R</td>
<td>Horizon</td>
<td>Thyroid eye disease, dcSSc</td>
<td>I/II II III III</td>
</tr>
</tbody>
</table>

### Programs Incorporating Genmab’s Innovation

<table>
<thead>
<tr>
<th>Product</th>
<th>Developed by</th>
<th>Indication(s)</th>
<th>Most Advanced Dev. Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amivantamab</td>
<td>DuoBody</td>
<td>NSCLC¹</td>
<td></td>
</tr>
<tr>
<td>Teclistamab</td>
<td>DuoBody</td>
<td>R/R MM</td>
<td></td>
</tr>
<tr>
<td>Talquetamab</td>
<td>DuoBody</td>
<td>R/R MM</td>
<td></td>
</tr>
<tr>
<td>Camidanlumab tesirine</td>
<td>UltiMAb™</td>
<td>ADC Therapeutics, R/R Hodgkin lymphoma, Solid tumors</td>
<td>II III III</td>
</tr>
<tr>
<td>PRV-015 (AMG 714)</td>
<td>UltiMAb™</td>
<td>Prevention Bio, Celiac disease</td>
<td>II III III</td>
</tr>
<tr>
<td>Minibody</td>
<td>DuoBody</td>
<td>Novo Nordisk</td>
<td>Hemophilia A</td>
</tr>
<tr>
<td>JNU-5201201</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>AML</td>
</tr>
<tr>
<td>JNU-5258501</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>JNU-7658124</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>R/R AML, MDS</td>
</tr>
<tr>
<td>JNU-672159002</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>HuMax-IL8</td>
<td>UltiMAb™</td>
<td>BMS</td>
<td>Adv. cancers</td>
</tr>
<tr>
<td>Lu AF82422</td>
<td>UltiMAb™</td>
<td>Lundbeck</td>
<td>Parkinson’s</td>
</tr>
</tbody>
</table>

¹Certain product candidates in development with partners, as noted. ²Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc. ³Products developed and marketed by others incorporating Genmab technology and innovation. ⁴See local country prescribing information for precise indications. ⁵Products under development by a third-party incorporating Genmab’s technology and innovation.

### Proprietary Technologies Allow us to Build a World-class Pipeline

#### DuoBody Platform
- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

#### HexaBody Platform
- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

#### DuoHexaBody Platform
- Antibody technology that combines DuoBody & HexaBody platforms
- Creates bispecific antibodies with target mediated enhanced potency

#### HexElect Platform
- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

### Executive Management:
- Jan G. J. van de Winkel, Ph.D., President & CEO
- Anthony Pagano, EVP & CFO
- Judith Klimovsky M.D., EVP & CDO
- Anthony Mancini, EVP & COO
- Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO, Head of Experimental Medicines

For more information/contact: genmab.com / ir@genmab.com

---

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. June 10, 2021.